Company / R&D Expense
ORAMED PHARMACEUTICALS INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$6.3M
FY2025
5-year range
$6.3M / $27.6M
FY2021-FY2025
Trend
-29.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $3M in FY2016 to $28M in FY2023.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of -14.1%.
Declined from $28M to $6M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -33.0%
- 5-Year CAGR
- -14.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -14.1%, indicating a declining trend.
- In FY2025, r&d expense decreased 29.5% year-over-year.
- Peak r&d expense was recorded in FY2023.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.3M | -29.5% |
| FY2024 | $9.0M | -67.5% |
| FY2023 | $27.6M | +31.7% |
| FY2022 | $21.0M | +105.1% |
| FY2021 | $10.2M | -24.3% |
| FY2020 | $13.5M | +31.5% |
| FY2019 | $10.3M | +33.4% |
| FY2018 | $7.7M | +61.2% |
| FY2017 | $4.8M | +45.9% |
| FY2016 | $3.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026